Navigation Links
Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
Date:1/31/2013

WASHINGTON, Jan. 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) today announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of tasimelteon as a monotherapy in the treatment of patients with MDD.  The clinical study did not meet the primary endpoint of change from baseline in the Hamilton Depression Scale (HAMD-17) after 8 weeks of treatment as compared to placebo.  Both tasimelteon and placebo treated patients had an approximately 40% reduction of their MDD symptoms from baseline.  Tasimelteon was shown to be safe and well-tolerated, consistent with observations in prior studies.  Given these current proof of concept clinical study results, Vanda has decided to discontinue all activities in this indication.

"These results are disappointing, as there is still a significant unmet medical need for patients with Major Depression," said Mihael H. Polymeropoulos , M.D., President and CEO of Vanda.  "Tasimelteon's application in the treatment of blind individuals with Non-24 remains our top priority as we pursue our planned NDA submission this year."     

Vanda has recently reported positive results in two phase III clinical studies of tasimelteon in Non-24-Hour Disorder (Non-24) and plans to submit a New Drug Application to the U.S. Food and Drug Administration in mid-2013.

About MAGELLAN

MAGELLAN was a proof of concept, two arm (tasimelteon 20mg and placebo), 8-week, double-masked, randomized, phase IIb/III clinical study in patients with MDD.  The study enrolled 507 patients in 43 sites in the U.S.  The primary endpoint of the study was the change from baseline in the Hamilton Depression Scale (HAMD-17) at week 8. 


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Reports First Quarter 2012 Results
2. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
3. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
4. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
5. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
6. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
7. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
8. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
9. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
10. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
11. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... -- It may seem like an odd pairing: an oral growth ... were two of the most talked about topics at ENDO ... Expo that just convened in San Francisco ... of the top internal medicine experts in the world is ... can not only save lives, but help people feel and ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... (the "Company") announced today that VPII Escrow Corp., a ... has launched its offer of approximately $3.2 billion aggregate ... Notes will be due in 2021 and in 2023, ... Company intends to use the net proceeds from the ...
(Date:6/18/2013)... , June 18, 2013 Valeant Pharmaceuticals International, ... has priced its previously announced public offering of common ... will issue 23,529,412 common shares at a price of ... $2.0 billion. The Company will file a final prospectus ... S-3 and will make a similar filing with the ...
Breaking Medicine Technology:"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... CINCINNATI, April 1, 2011 CarePoint Partners, one of ... in the United States, launched a food drive today ... the less fortunate in the communities where it operates. ... conducted throughout the month of April. CarePoint Partners is ...
... Inc. (OTCBB: PLCSF), a company focused on innovative medical ... REMEDIAL II investigator-sponsored clinical trial of its RenalGuard System™ ... a.m. CT on Monday, April 4, 2011, at the ... & Expo in New Orleans, Louisiana. Additionally, PLC will ...
Cached Medicine Technology:CarePoint Partners Kicks Off Food Drive to Help Fight Hunger in Twenty-One Local Communities 2REMEDIAL II Results on PLC System's RenalGuard® to be Presented at ACC 2011's Late Breaking Clinical Trial Session 2REMEDIAL II Results on PLC System's RenalGuard® to be Presented at ACC 2011's Late Breaking Clinical Trial Session 3
(Date:6/19/2013)... (PRWEB) June 19, 2013 Guests at the ... wealthy and wise even if they don’t go to bed ... require some early thought. , Crafty travelers ... they take advantage of the pet-friendly Scottsdale Paradise Valley hotel’s ... . With at least 14 days advance notice, guests can ...
(Date:6/19/2013)... 19, 2013 At a Travel Services Member ... and growth that has occurred over the last year since ... Shuman said, "Travel Services has added vendors, lowered prices of ... Membership is up, even in the tough economy, and ... of members." , Having been in the Travel Business and ...
(Date:6/19/2013)... June 19, 2013 Amerinet, Inc, ... ARAMARK Healthcare Technologies to help Pacific Medical Centers ... savings of more than 17 percent over the ... expenditures. , “Driving economies of scale and process ... management challenges facing multi-site providers,” said Shawn Padilla, ...
(Date:6/19/2013)... The motor neuron disease Amyotrophic lateral sclerosis (ALS), also ... sequential pattern which can be classified into four distinct ... at the University of Pennsylvania in the Annals ... and spinal cord tissues shows, for the first time, ... starting point in the central nervous system to other ...
(Date:6/19/2013)... pushed to the brink of extinction but can we ... questions which a Bristol academic addresses in his new book, ... at the University of Bristol, has produced the first comprehensive ... the story of polio explores the experiences of victims alongside ... disease. , According to a review by ...
Breaking Medicine News(10 mins):Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Amerinet Partners with ARAMARK Healthcare Technologies to Help Pacific Medical Centers Save 17 Percent and Better Manage System-Wide Equipment Program 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Paralysed with fear: The story of polio 2
... Congressman Chaka Fattah (D-PA) issues the following statement upon ... insurance program by a bipartisan vote of 289 to 139. ... "The effort to bring change to Washington by expanding health ... major stride today. I have joined with more than two-thirds ...
... They and blacks still share outcome disparities in treatment of ... -- The standard treatment for hepatitis C does not appear ... as it helps non-Hispanic whites, a new study suggests. , ... blacks -- found not to respond well to the therapy, ...
... U.S. and around the world, researchers say , , WEDNESDAY, Jan. ... in the operating room is on the same page reduces ... improving safety in surgery is vital since there are some ... them in the United States. In fact, the average American ...
... 14 The National Council of Legislators from ... of lawmakers from states with casinos and other ... resolution Saturday encouraging states to take action ... adopted at the NCLGS 2009 Winter Meeting, held ...
... CHICAGO, Jan. 14 In celebration of Inauguration Day, ... customers all day on,Tuesday, Jan. 20. , ... Original chilled yogurt that was,previously topped with blueberries, blue ... color. Now in the spirit of,patriotism, the special combination ...
... The following is a statement from Matthew ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )Baltimore Mayor Sheila Dixon and Baltimore City ... protect the city,s children and health by issuing ... individual, cheap cigars. Under the regulation, cheap cigars ...
Cached Medicine News:Health News:Hispanics Respond Poorly to Standard Hepatitis C Therapy 2Health News:Surgeon's Checklist Saves Lives 2Health News:Surgeon's Checklist Saves Lives 3Health News:National Council of Legislators From Gaming States Adopts Resolution Supporting 100% Smokefree Gaming Venues 2Health News:Inauguration Day Deal: Get a Free Berry Obama Chilled Yogurt at Berry Chill 2Health News:Baltimore's Ban on Sale of Single, Cheap Cigars Will Protect Kids and Health 2
... The DNA Engine instrument is ... Unprecedented thermal uniformity and ... and block-to-block. This rugged ... cycler, it's a platform for new ...
... up kit. Includes configured Laptop PC with ... 1 MultiBlock satellite thermal Cycler (non-robotic). ... friendly software. Store/track run data. ... Outstanding uniformity. Advanced control algorithms ...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
96 well format, Gradient features tests 12 PCR annealing temperatures in 1 run...
Medicine Products: